CA2748496C - Disintegrable formulations of lanthanum carbonate - Google Patents

Disintegrable formulations of lanthanum carbonate Download PDF

Info

Publication number
CA2748496C
CA2748496C CA2748496A CA2748496A CA2748496C CA 2748496 C CA2748496 C CA 2748496C CA 2748496 A CA2748496 A CA 2748496A CA 2748496 A CA2748496 A CA 2748496A CA 2748496 C CA2748496 C CA 2748496C
Authority
CA
Canada
Prior art keywords
dosage form
pharmaceutical dosage
lanthanum carbonate
excipient
disintegrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2748496A
Other languages
English (en)
French (fr)
Other versions
CA2748496A1 (en
Inventor
Andrea Blum Works
John Twist
Okey Noe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Inc
Original Assignee
Mylan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Inc filed Critical Mylan Inc
Publication of CA2748496A1 publication Critical patent/CA2748496A1/en
Application granted granted Critical
Publication of CA2748496C publication Critical patent/CA2748496C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2748496A 2009-01-21 2010-01-21 Disintegrable formulations of lanthanum carbonate Active CA2748496C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14616209P 2009-01-21 2009-01-21
US61/146,162 2009-01-21
PCT/US2010/021573 WO2010085520A1 (en) 2009-01-21 2010-01-21 Disintegrable formulations of lanthanum carbonate

Publications (2)

Publication Number Publication Date
CA2748496A1 CA2748496A1 (en) 2010-07-29
CA2748496C true CA2748496C (en) 2019-02-26

Family

ID=42356194

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2748496A Active CA2748496C (en) 2009-01-21 2010-01-21 Disintegrable formulations of lanthanum carbonate

Country Status (10)

Country Link
US (1) US8962036B2 (cg-RX-API-DMAC7.html)
EP (1) EP2389070B1 (cg-RX-API-DMAC7.html)
JP (1) JP5643227B2 (cg-RX-API-DMAC7.html)
CA (1) CA2748496C (cg-RX-API-DMAC7.html)
ES (1) ES2433076T3 (cg-RX-API-DMAC7.html)
PL (1) PL2389070T3 (cg-RX-API-DMAC7.html)
PT (1) PT2389070E (cg-RX-API-DMAC7.html)
SI (1) SI2389070T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010085520A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105577B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0640812B2 (ja) 1987-10-28 1994-06-01 雪印乳業株式会社 醗酵室
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
WO2016051609A1 (ja) * 2014-10-02 2016-04-07 東和薬品株式会社 粒度調整された炭酸ランタン水和物からなる医薬
JP2016147827A (ja) * 2015-02-12 2016-08-18 株式会社三和化学研究所 炭酸ランタン水和物を含有する医薬製剤
CN112724039A (zh) 2015-04-20 2021-04-30 艾德凡斯化学公司 包括烷基肟的涂料组合物
EP4061340A4 (en) 2019-11-21 2023-08-09 Santa Farma Ilaç Sanayi A.S. ORAL SOLID PHARMACEUTICAL COMPOSITIONS WITH LANTANHANE CARBONATE OCTAHYDRATE
CN115813867B (zh) * 2022-12-01 2024-05-24 山东齐都药业有限公司 碳酸镧冻干片及其制备方法
JP2025044388A (ja) * 2023-09-20 2025-04-02 株式会社東芝 酸性ガス除去方法、酸性ガス吸収剤、および酸性ガス除去装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3371531B2 (ja) * 1994-04-20 2003-01-27 株式会社豊田中央研究所 触媒の製造方法
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
DK2792363T3 (da) * 2003-08-26 2016-09-26 Shire Biopharmaceuticals Holdings Ireland Ltd Farmaceutisk formulering, der omfatter lanthanforbindelser
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
WO2007022466A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Hyperphosphatemia in domestic animals: compositions and methods of treatment
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form

Also Published As

Publication number Publication date
SI2389070T1 (sl) 2013-11-29
PL2389070T3 (pl) 2014-01-31
ES2433076T3 (es) 2013-12-09
JP5643227B2 (ja) 2014-12-17
HK1163452A1 (en) 2012-09-14
EP2389070A1 (en) 2011-11-30
EP2389070B1 (en) 2013-07-31
PT2389070E (pt) 2013-10-21
CA2748496A1 (en) 2010-07-29
US20110280967A1 (en) 2011-11-17
US8962036B2 (en) 2015-02-24
WO2010085520A1 (en) 2010-07-29
EP2389070A4 (en) 2012-07-11
JP2012515723A (ja) 2012-07-12
ZA201105577B (en) 2014-01-29

Similar Documents

Publication Publication Date Title
EP2389070B1 (en) Disintegrable formulations of lanthanum carbonate
AU2022204380B2 (en) Pharmaceutical composition, comprising phosphate binder particles
KR101438071B1 (ko) 약학 조성물
CN1871018B (zh) 包含镧化合物的药物制剂
EP3210600B1 (en) Mixed metal compounds used as antacids
EP2395972A1 (en) Particulate composition and the method of making the same
JP2015537013A (ja) 速崩性錠剤
HK1163452B (en) Disintegrable formulations of lanthanum carbonate
KR20180060705A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
HK40040722A (en) Pharmaceutical composition, comprising phosphate binder particles

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250114

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250114

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260113

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260113